

Cisplatin resistance in urothelial carcinoma

Citation for published version (APA):

Skowron, M. (2018). *Cisplatin resistance in urothelial carcinoma: Understanding and targeting inherent and acquired mechanisms*. Proefschriftmaken.nl || Uitgeverij BOXPress.
<https://doi.org/10.26481/dis.20180607ms>

Document status and date:

Published: 01/01/2018

DOI:

[10.26481/dis.20180607ms](https://doi.org/10.26481/dis.20180607ms)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:


www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.



Propositions

belonging to the thesis

Cisplatin resistance in urothelial carcinoma

Understanding and targeting inherent and acquired mechanisms

1. CD90⁺/CK14⁺ do not specifically mark cancer stem cells in urothelial carcinoma cell lines and do not correlate under various conditions (*this dissertation*).
2. Long-term cisplatin treated urothelial carcinoma cell lines (LTTs) evade cisplatin induced cell death through phenotypic plasticity towards an EMT-like phenotype (*this dissertation*).
3. Each LTT contains an individual assortment of resistance mechanisms at multiple levels (*this dissertation*).
4. Approaches targeting individual resistance mechanisms are only partly efficacious (*this dissertation*).
5. The chicken chorioallantoic membrane (CAM) assay is an attractive 3D model to study urothelial carcinoma and can be used as an alternative approach to murine *in vivo* studies; however, the short timing can be a limiting factor (*this dissertation*).
6. It is an old saying, abundantly justified, that where sciences meet there growth occurs. - *Sir Frederick Gowland Hopkins*
7. Success in research needs persistence and consequence.
8. I have not failed. I've just found 10,000 ways that won't work. - *Thomas Edison*
9. The conviction that the right approach to solve the task is to do it rationally does not prevent a scientist from hoping for unexpected lucky coincidence, serendipity.
10. A scientist in his laboratory is not a mere technician; he is also a child confronting natural phenomena that impress him as though they were fairy tales. - *Maria Skłodowska-Curie*
11. What people call serendipity sometimes is just having your eyes open. - *Jose Manuel Barroso*

Margaretha A. Skowron
Maastricht, June 7th, 2018

